Dr. Dennis Stuehr

past PResident

Cleveland ClinicCleveland, USA

Dennis J. Stuehr received his BS degree in Chemistry from Bowling Green State University in 1980, and a PhD in Toxicology with Dr. Michael Marletta at The Massachusetts Institute of Technology in 1987, during which time they in collaboration with Dr. Steven Tannenbaum performed some of the earliest investigations into mammalian nitrogen oxide biosynthesis. In 1987 Dr. Stuehr moved to Cornell University Medical College and continued his work as a Leukemia Society Fellow with Dr. Carl Nathan, and joined the faculty in 1989 as an Assistant Professor. In 1991 Dr. Stuehr moved to The Cleveland Clinic where he presently is a Member in the Department of Pathobiology, Lerner Research Institute, and a Professor of Molecular Medicine in the Medical School. He is a founding member of the NO society, the NO Journal, and the NO Gordon Conference. Dr. Stuehr’s research interests include the molecular regulation of NO synthases, the cell biology of heme protein maturation, and the influence of NO on heme trafficking and soluble guanylate cyclase dysfunction in asthma.

Currently President of our Society, Phil is Chair in Cardiovascular Metabolism and Associate Dean (Research) at the School of Health Sciences, Cardiff Metropolitan University. He directs all post-graduate research, Chairs the Research Ethics Committee and Chairs the Research & Enterprise committee. He is a Faculty member (Health and Care Research Wales) and on the Executive committee of the Wales Heart Research Institute.

His research very much focusses on nitric oxide metabolism in patient cohorts. With significant funding from the British Heart Foundation, current projects include therapeutic application of nitrite/nitrate in coronary artery disease patients (NSTEMI) and influence of dietary NOx on current antiplatelet therapies. Phil is also drawn by the role(s) of cell derived microvesicles, and in particular how circulating microvesicles from platelets and adipocytes influence endothelial and vascular function in the setting of metabolic syndrome and diabetes.  

Dr. Philip E. James


Cardiff School of Health Sciences, Cardiff Metropolitan UniversityCardiff, UK

Screenshot 2017-01-08 09.53.40.png
Screenshot 2017-01-08 09.53.49.png

Dr. Nathan S. Bryan


Baylor College of MedicineHouston, USA

Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University School of Medicine in Shreveport where he was the recipient of the Dean’s Award for Excellence in Research.  He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute.  After a two year post-doctoral fellowship, in 2006 Dr. Bryan was recruited to join faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology.  During his tenure as faculty and independent investigator at UT, his research focused on drug discovery through screening natural product libraries for active compounds.  His nine years at UT led to several discoveries which have resulted in eight issued US and international patents and nine pending worldwide.  He is also a successful entrepreneur who has commercialized his nitric oxide technology through the formation of Human, to the Power of N, Inc (formerly Neogenis Labs) where he is Founder and Chief Science Officer.  Dr. Bryan has been involved in nitric oxide research for the past 16 years and has made many seminal discoveries in the field.  These discoveries and findings have transformed the development of safe and effective functional bioactive natural products in the treatment and prevention of human disease and may provide the basis for new preventive or therapeutic strategies in many chronic diseases.  Dr. Bryan has published a number of highly cited papers and authored or edited 5 books.  He is an international leader in molecular medicine and natural product chemistry.


Dr. Douglas D. Thomas


Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at ChicagoChicago





Prof. Takaaki Akaike

Department of Environmental Health Sciences and Molecular Toxicology

Tohoku University Graduate School of MedicineSendai, Japan

Screenshot 2017-01-08 09.54.16.png

Dr. Claudia R. Morris

Claudia R. Morris, M.D., FAAP

Associate Professor of Pediatrics and Emergency Medicine

Department of Pediatrics, Division of Pediatric Emergency Medicine

Emory-Children’s Center for Cystic Fibrosis and Airways Disease Research

Emory University School of Medicine, Atlanta, Georgia



Dr. Claudia R. Morris, MD is an Associate Professor of Pediatrics and Emergency Medicine at Emory University School of Medicine. She is also an attending physician in Pediatric Emergency Medicine (PEM) at Children’s Healthcare of Atlanta. She received her medical degree at Eastern Virginia Medical School in 1993, and completed her residency training in Pediatrics at Children’s Hospital Oakland in 1996. She went on to do a chief resident year, as well a fellowship in PEM at Children’s Hospital Oakland, and remained on as faculty until her relocation to Emory in 2012.

Her first exposure to nitric oxide research was under the mentorship of Drs. Carl Nathan MD and Dennis Stuehr PhD at Cornell University Medical College in 1987-1988. She was able to translate what she learned about the arginine-nitric oxide pathway in their lab as a research technician to the study of sickle cell disease a decade later that has led to several promising clinical trials of arginine therapy.

The goal of her research efforts is to develop novel interventions that minimize inflammation, hemolysis and morbidity in these disorders, targeting the arginine-nitric oxide pathway.  She is delighted to serve on the Board for the Nitric Oxide Society. 


Dr. Sruti Shiva

Department of Pharmacology & Chemical Biology, The Vascular Medicine Institute

University of PittsburghPittsburgh, USA

Sruti Shiva completed her PhD at the University of Alabama at Birmingham and after a postdoctoral fellowship at the Heart Lung and Blood Institute at the NIH, Sruti joined the faculty of the University of Pittsburgh in 2008.  She is currently an Associate Professor in the Department of Pharmacology & Chemical Biology and a Principal Investigator in the Vascular Medicine Institute.  She is also Co-Director of the Center for Metabolism and Mitochondrial Medicine.  Dr. Shiva’s research focuses broadly on understanding the mechanisms by which reactive nitrogen and oxygen species interact with mitochondria to regulate the signaling functions of this organelle, and the implications of this mitochondrial-redox signaling for cardiovascular physiology and disease pathogenesis. 



Prof. Yasuo Watanabe

Laboratory of Pharmacology


Biennial Conference Chair


Radcliffe Department of Medicine, University of OxfordOxford, UK

(ex-officio, non-voting)

Mark graduated from the University of Surrey in 2001 and followed this with a collaborative PhD with Professor Steven S. Gross at Weill Cornell Medical College, New York USA in 2005 (also with the University of Surrey). Having spent 4 years in New York City he returned to the UK taking up a Postdoctoral Scientist position in the lab of Professor Keith Channon at the University of Oxford. He is now a British Heart Foundation Basic Science Intermediate Fellow and University Research Lecturer with his own group studying NO biology and Redox signalling in cardiovascular disease. 

NO and reactive oxygen species (ROS) are critical regulatory molecules in cardiovascular function. In diseases such as diabetes and high blood pressure, NO production is decreased and the balance between NO and ROS is disturbed. Drugs to decrease ROS, called ‘antioxidants’ have no clinical benefit, but this probably reflects our poor understanding of how NO and ROS are produced and have their effects in cells. Mark’s laboratory is using proteomic approaches, combined with the use of fluorescent biosensors to investigate how NO/ROS balance affects cell signalling, with the aim of identifying specific mechanisms and proteins that will provide new targets for future cardiovascular drug treatments. Mark is particularly interested in the wider impact of subcellular-specific changes in NO-redox balance and the discovery of new redox-related proteins and pathways that govern these effects.




PresidentDr. Dennis Stuehr  Email 

President-ElectDr. Philip James  Email

Secretary TreasurerDr. Nathan Bryan  Email

Executive Committee Member at LargeDr. Douglas Thomas  Email


CouncilorDr. Sruti Shiva  Email

CouncilorProf. Takaaki Akaike  Email

CouncilorDr. Claudia Morris  Email

CouncilorProf. Yasuo Watanabe  Email

Biennial Conference Chair

Ex-officio, non-votingDr. Mark Crabtree  Email